Bristol Gate Capital Partners, an investment management company, published its Q3 2025 investor letter for the “US Equity Strategy”. A copy of the letter can be downloaded here. The strategy underperformed the benchmark, the S&P 500® Total Return Index, this quarter, but still surpassed the index in dividend growth. The underperformance was due to a lack of significant exposure to the AI/TMT sector or the Value sector, which provides advantages stemming from the Federal Reserve's rate cut. The portfolio ret ...

Group 1 - Thermo Fisher Scientific Inc. (NYSE:TMO) has faced challenges due to COVID-19, with comparisons made to Danaher, which is perceived to have a stronger position currently [1][2] - Jim Cramer highlighted that while Thermo Fisher is a great company led by Marc Casper, he recommends Danaher for investment, indicating a preference for DHR over TMO [1][2] - Cramer advised against purchasing Thermo Fisher stock until there is an improvement in Chinese orders, citing the stock's recent struggles and its connection to the bearish outlook on China [2] Group 2 - The company provides a range of services including life sciences solutions, analytical instruments, diagnostics, lab products, and biopharma services [2] - There is a belief that certain AI stocks may offer better investment opportunities with higher upside potential and lower downside risk compared to Thermo Fisher [2]